JP2008505177A - 目の障害および状態を治療するための組成物および方法 - Google Patents
目の障害および状態を治療するための組成物および方法 Download PDFInfo
- Publication number
- JP2008505177A JP2008505177A JP2007520365A JP2007520365A JP2008505177A JP 2008505177 A JP2008505177 A JP 2008505177A JP 2007520365 A JP2007520365 A JP 2007520365A JP 2007520365 A JP2007520365 A JP 2007520365A JP 2008505177 A JP2008505177 A JP 2008505177A
- Authority
- JP
- Japan
- Prior art keywords
- omega
- composition
- fatty acid
- acid
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 199
- 238000000034 method Methods 0.000 title claims abstract description 42
- 208000030533 eye disease Diseases 0.000 title description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 76
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 70
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract description 70
- 229940033080 omega-6 fatty acid Drugs 0.000 claims abstract description 69
- 239000006014 omega-3 oil Substances 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 58
- 206010013774 Dry eye Diseases 0.000 claims description 58
- 239000004094 surface-active agent Substances 0.000 claims description 48
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 36
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 27
- 239000003889 eye drop Substances 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 25
- 229940012356 eye drops Drugs 0.000 claims description 23
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 235000021342 arachidonic acid Nutrition 0.000 claims description 18
- 229940114079 arachidonic acid Drugs 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 17
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 17
- 230000004054 inflammatory process Effects 0.000 claims description 17
- 235000020778 linoleic acid Nutrition 0.000 claims description 17
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 17
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 16
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 16
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 16
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 16
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 14
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 14
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 14
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 13
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 13
- 229960002733 gamolenic acid Drugs 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000013268 sustained release Methods 0.000 claims description 11
- 239000012730 sustained-release form Substances 0.000 claims description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 10
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 9
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 229960004488 linolenic acid Drugs 0.000 claims description 7
- -1 omega-3 fatty acid compound Chemical class 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 6
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical class COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical group FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 55
- 235000014113 dietary fatty acids Nutrition 0.000 description 50
- 229930195729 fatty acid Natural products 0.000 description 50
- 239000000194 fatty acid Substances 0.000 description 50
- 150000004665 fatty acids Chemical class 0.000 description 50
- 210000001508 eye Anatomy 0.000 description 47
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 36
- 238000010186 staining Methods 0.000 description 36
- 239000003981 vehicle Substances 0.000 description 30
- 239000006196 drop Substances 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000004087 cornea Anatomy 0.000 description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 14
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 14
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 14
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 14
- 229960002646 scopolamine Drugs 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 230000028327 secretion Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 150000002066 eicosanoids Chemical class 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 230000004489 tear production Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229960000711 alprostadil Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 230000004488 tear evaporation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 239000003618 borate buffered saline Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 229940113601 irrigation solution Drugs 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical group CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001730 Familial dysautonomia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 201000001638 Riley-Day syndrome Diseases 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000035623 congenital anemia Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229920013746 hydrophilic polyethylene oxide Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58451404P | 2004-07-01 | 2004-07-01 | |
| PCT/US2005/023113 WO2006007510A1 (en) | 2004-07-01 | 2005-06-30 | Compositions and methods for treating eye disorders and conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505177A true JP2008505177A (ja) | 2008-02-21 |
| JP2008505177A5 JP2008505177A5 (cg-RX-API-DMAC7.html) | 2008-12-04 |
Family
ID=35784207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007520365A Pending JP2008505177A (ja) | 2004-07-01 | 2005-06-30 | 目の障害および状態を治療するための組成物および方法 |
Country Status (15)
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2012067224A1 (ja) * | 2010-11-19 | 2014-05-19 | 日本水産株式会社 | 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤 |
| JP2014518261A (ja) * | 2011-06-30 | 2014-07-28 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド | 眼の炎症状態を治療するためのエステル |
| KR20150054997A (ko) * | 2012-09-12 | 2015-05-20 | 노바리크 게엠베하 | 부분불소화 알칸 조성물 |
| JP2015526515A (ja) * | 2012-08-31 | 2015-09-10 | ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ | オメガ３脂肪酸を有する眼用組成物 |
| JP2015531344A (ja) * | 2012-09-12 | 2015-11-02 | ノバリック ゲーエムベーハー | 半フッ化アルカンの混合物を含む組成物 |
| JP2016512245A (ja) * | 2013-03-12 | 2016-04-25 | フィジシャンズ レコメンデッド ニュートリシューティカルズ エルエルシーＰｈｙｓｉｃｉａｎｓ Ｒｅｃｏｍｍｅｎｄｅｄ Ｎｕｔｒｉｃｅｕｔｉｃａｌｓ，Ｌｌｃ | マイボーム腺を標的とする栄養補給剤 |
| US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| JP2021529167A (ja) * | 2018-06-19 | 2021-10-28 | エーパックス ノルウェー アクスイェ セルスカプ | ドライアイ疾患及び瞼板腺炎の治療のための組成物 |
| US11160865B2 (en) | 2010-10-20 | 2021-11-02 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US12496326B2 (en) | 2016-12-23 | 2025-12-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060251685A1 (en) * | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
| AU2005296212A1 (en) * | 2004-10-19 | 2006-04-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Topical treatment with NGF and DHA in damaged corneas |
| US20070293410A1 (en) * | 2006-06-15 | 2007-12-20 | Surowiak Richard J | Contact lens and method for preventing contact lens intolerance |
| CA2704371A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| IT1393419B1 (it) * | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| EP2437762B1 (en) | 2009-06-05 | 2017-08-09 | Allergan, Inc. | Artificial tears and therapeutic uses |
| WO2011103514A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha triglyceride emulsions |
| US20110200645A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Free Fatty Acid Emulsions |
| US20110200644A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Ester Emulsions |
| DE102010050570A1 (de) | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors |
| WO2012145119A2 (en) * | 2011-04-17 | 2012-10-26 | Michael Gurin | Low inflammatory blended oils |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| EP2714010B1 (en) | 2011-05-25 | 2017-03-01 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
| US20160310456A1 (en) * | 2013-03-12 | 2016-10-27 | Physicians Recommended Nutriceuticals, Llc | Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure |
| HRP20151039T1 (hr) * | 2011-09-12 | 2015-11-20 | Tassos GEORGIOU | Upotreba omega masnih kiselina za lijeäśenje bolesti |
| US8957048B2 (en) * | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| DK2806886T3 (en) | 2012-01-23 | 2017-06-06 | Novaliq Gmbh | STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES |
| CA2867168A1 (en) | 2012-03-30 | 2013-10-03 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
| US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
| US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| EP2664330A1 (de) | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan |
| US8673325B1 (en) * | 2012-09-06 | 2014-03-18 | Dignity Sciences Limited | Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| CN105050556B (zh) | 2013-02-26 | 2017-06-06 | 贝尔金激光有限公司 | 用于青光眼治疗的系统 |
| WO2015042442A1 (en) * | 2013-09-19 | 2015-03-26 | Dignity Sciences Limited | Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof |
| AU2015270418B2 (en) | 2014-06-04 | 2020-08-06 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and use of same |
| JP6768653B2 (ja) | 2014-11-25 | 2020-10-14 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 安定したオメガ−３眼科用組成物 |
| EP3229908A4 (en) * | 2014-12-12 | 2018-06-27 | Schepens Eye Research Institute. Inc. | Gdnf induction for the treatment of retinal disorders |
| EP3294282A1 (en) | 2015-05-13 | 2018-03-21 | DS Biopharma Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| JP2018520197A (ja) | 2015-07-21 | 2018-07-26 | アフィミューン リミテッド | 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物 |
| KR20180094516A (ko) | 2015-12-18 | 2018-08-23 | 애피뮨 리미티드 | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 |
| CN106963728A (zh) * | 2016-01-13 | 2017-07-21 | 汤欣 | 一种二十二碳六烯酸结膜下注射液的制备方法及其应用 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| JP7500550B2 (ja) | 2018-10-12 | 2024-06-17 | ノバリック ゲーエムベーハー | 乾性眼疾患の治療のための眼科用組成物 |
| WO2020165132A1 (en) | 2019-02-13 | 2020-08-20 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| ES2982698T3 (es) * | 2020-01-23 | 2024-10-17 | Visufarma S P A | Composición oftálmica para el tratamiento de la enfermedad del ojo seco |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63297323A (ja) * | 1987-05-07 | 1988-12-05 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツ プリカーシヨン・シヤンテイフイツク・（エス．セー．エール．アー．エス） | 眼科薬 |
| JPH06122627A (ja) * | 1992-10-13 | 1994-05-06 | Sagami Chem Res Center | 抗アレルギー点眼液 |
| WO2003018049A2 (en) * | 2001-08-23 | 2003-03-06 | Westgate Biological Limited | Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| JP2003512312A (ja) * | 1999-10-20 | 2003-04-02 | ヴェジファクト・アクチェンゲゼルシャフト | マイクロエマルジョン予備濃縮物、マイクロエマルジョンおよび組成物の使用 |
| WO2004004599A2 (en) * | 2002-07-08 | 2004-01-15 | Advanced Vision Research | Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| JP2005008570A (ja) * | 2003-06-19 | 2005-01-13 | Santen Pharmaceut Co Ltd | 角膜疾患治療剤 |
| JP2006526579A (ja) * | 2003-03-18 | 2006-11-24 | アドバンスト メディカル オプティクス， インコーポレーテッド | 自己乳化組成物、その使用および製造方法 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US437014A (en) * | 1890-09-23 | Swing | ||
| US3572913A (en) * | 1969-02-03 | 1971-03-30 | Boylston Res Ass | Comprehensive support for ophthalmic examination apparatus and instruments |
| US4056496A (en) * | 1972-10-02 | 1977-11-01 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
| US3957362A (en) * | 1972-10-02 | 1976-05-18 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
| US4401372A (en) * | 1972-10-02 | 1983-08-30 | Syntex (U.S.A.) Inc. | Contact lens |
| US4180308A (en) * | 1972-10-02 | 1979-12-25 | Syntex (Usa) Inc. | Contact lens |
| DE2309440A1 (de) * | 1973-02-26 | 1974-09-05 | Katz | Verfahren zum isolieren von lysozym |
| US3991759A (en) | 1975-10-28 | 1976-11-16 | Alza Corporation | Method and therapeutic system for treating aqueous deficient dry eye |
| US4313355A (en) * | 1978-02-06 | 1982-02-02 | Syntex (U.S.A.) Inc. | Method and apparatus for manufacturing plastic lenses |
| US4202226A (en) * | 1978-02-06 | 1980-05-13 | SyntexLaboratories, Inc. | Method and apparatus for manufacturing plastic lenses |
| US4338419A (en) * | 1979-02-09 | 1982-07-06 | Syntex (U.S.A.) Inc. | Process for treatment of hydrogel lens with thiols |
| US4267295A (en) * | 1979-02-09 | 1981-05-12 | Syntex (U.S.A.) Inc. | Polymeric compositions and hydrogels formed therefrom |
| US4379864A (en) * | 1979-02-09 | 1983-04-12 | Syntex (U.S.A.) Inc. | Polymeric compositions and hydrogels formed therefrom |
| US4543371A (en) * | 1981-03-05 | 1985-09-24 | Syntex (U.S.A.) Inc. | Polymeric compositions and hydrogels formed therefrom |
| US5145686A (en) * | 1982-02-03 | 1992-09-08 | Efamol Limited | Topical pharmaceutical compositions |
| DE3368377D1 (en) | 1982-04-16 | 1987-01-29 | Nestle Sa | Lipid composition for oral, enteral or parenteral feeding |
| US4421748A (en) * | 1982-07-13 | 1983-12-20 | Trager Seymour F | Artificial tear aid |
| US4533399A (en) * | 1983-04-12 | 1985-08-06 | Minnesota Mining And Manufacturing Company | Contact lens cleaning method |
| US4678698A (en) * | 1983-04-12 | 1987-07-07 | Minnesota Mining And Manufacturing Company | Contact lens cleaning article |
| US4622258A (en) * | 1983-04-12 | 1986-11-11 | Minnesota Mining And Manufacturing Company | Contact lens cleaning article |
| JPS6158539A (ja) * | 1984-08-29 | 1986-03-25 | Nisshin Oil Mills Ltd:The | スナツク様菓子の製造法 |
| US4613380A (en) * | 1985-04-01 | 1986-09-23 | Dow Corning Corporation | Method for removing lipid deposits from contact lenses |
| US5484432A (en) * | 1985-09-27 | 1996-01-16 | Laser Biotech, Inc. | Collagen treatment apparatus |
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| US4801452A (en) * | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
| US5028599A (en) * | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
| US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
| US5078995A (en) * | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
| US5250294A (en) * | 1986-05-15 | 1993-10-05 | Emory University | Improved perfusion medium for transplantation of organs |
| US5017370A (en) * | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
| US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
| US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
| US5240701A (en) * | 1986-05-15 | 1993-08-31 | Emory University | Method of performing angioplasty procedures |
| US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
| US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
| US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5089260A (en) * | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
| US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
| US4997644A (en) * | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
| US5648071A (en) * | 1986-05-15 | 1997-07-15 | Emory University | Method of treating tumors |
| US5198211A (en) * | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
| US5047236A (en) * | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
| US4837014A (en) * | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
| US5032394A (en) * | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
| US5240702A (en) * | 1986-05-15 | 1993-08-31 | Emory University | Method of treating stroke |
| US5064643A (en) * | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
| US4937070A (en) * | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5080894A (en) * | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
| US5278151A (en) * | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| US4914088A (en) * | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| CA1263270A (en) * | 1987-08-19 | 1989-11-28 | Bruce J. Holub | Animal feed supplement |
| US5111221A (en) * | 1988-05-13 | 1992-05-05 | United States Of America As Represented By The Secretary Of The Navy | Receptor-based sensor |
| US5225374A (en) * | 1988-05-13 | 1993-07-06 | The United States Of America As Represented By The Secretary Of The Navy | Method of fabricating a receptor-based sensor |
| US4923700A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Artificial tear suspension |
| US4959048A (en) * | 1989-01-17 | 1990-09-25 | Helix Medical, Inc. | Lacrimal duct occluder |
| US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
| US5278142A (en) * | 1989-03-20 | 1994-01-11 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
| US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5206298A (en) * | 1989-12-19 | 1993-04-27 | Tomei Sangyo Kabushiki Kaisha | Graft copolymer, solution containing the graft copolymer for treating contact lens, and method of treating contact lens with the solution and making hydrophilic lens surface |
| ZA912797B (en) * | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| ATE132366T1 (de) * | 1990-05-29 | 1996-01-15 | Boston Ocular Res | Zusammensetzung zur behandlung von dry eye erkrankungen |
| US5167323A (en) * | 1990-08-09 | 1992-12-01 | Tomei Sangyo Co., Ltd. | Lens treating device for treating contact lens |
| US5181604A (en) * | 1990-09-14 | 1993-01-26 | Tomei Sangyo Co., Ltd. | Contact lens holder and treating device |
| US5203337A (en) * | 1991-05-08 | 1993-04-20 | Brigham And Women's Hospital, Inc. | Coronary artery imaging system |
| ZA927277B (en) * | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| US5469867A (en) * | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
| PH30249A (en) * | 1992-09-16 | 1997-02-05 | Zhejiang Provincial Hospital O | Neutral lipids from endosperm of job's tears |
| US5378488A (en) * | 1993-06-10 | 1995-01-03 | Abbott Laboratories | Aseptic processing of infant formula |
| HK1009336A1 (en) * | 1993-12-29 | 1999-05-28 | Bausch & Lomb Incorporated | Carbohydrate composition and method for cleaning and disinfecting contact lenses |
| US6060644A (en) * | 1994-03-24 | 2000-05-09 | Iowa State University Research Foundation, Inc. | Isolation and use of cuticular lipid genes |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US5861148A (en) * | 1995-01-23 | 1999-01-19 | Smith; Stewart Gregory | Ophthalmic compositions and process of using |
| US6113894A (en) * | 1995-01-23 | 2000-09-05 | Smith; S. Gregory | Ophthalmic compositions and process of using |
| EP0733918B1 (en) * | 1995-03-24 | 2003-07-30 | Ocular Research of Boston, Inc. | Hydrogel lens pre-coated with lipid layer |
| US5738856A (en) * | 1995-11-03 | 1998-04-14 | Ocular Research Of Boston, Inc. | Skin care preparation and method |
| WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| DE69725320T2 (de) * | 1996-08-02 | 2004-07-15 | Plum Kemi Produktion A/S | Oel-im-wasser emulsion zur gruendlichen reinigung, zum schutz oder verbesserung der haut |
| CZ146598A3 (cs) * | 1996-09-20 | 1998-11-11 | Atherogenics, Inc. | Způsob diagnostikování mediatoru zánětlivých poruch |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| JPH10218760A (ja) | 1997-02-04 | 1998-08-18 | Nobel Igaku Kenkyusho:Kk | ドライアイ治療用の微量油添加目薬 |
| EP1098199B1 (en) * | 1997-03-03 | 2008-07-23 | Adcock Ingram Limited | A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease |
| JP4330268B2 (ja) * | 1997-09-03 | 2009-09-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 新規な生体模倣ヒドロゲル材料 |
| US6475784B1 (en) * | 1997-11-14 | 2002-11-05 | Valentis, Inc. | Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides |
| US5981607A (en) * | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| EP1082966A4 (en) | 1998-05-15 | 2004-07-21 | Wakamoto Pharma Co Ltd | ANTI-INFLAMMATORY EYE DROPS |
| US6346594B1 (en) * | 1998-09-21 | 2002-02-12 | Menicon Co., Ltd. | Ocular lens material and process for producing same |
| CA2362498A1 (en) * | 1999-03-01 | 2000-09-08 | Vista Scientific Llc | Mucin containing ophthalmic preparations |
| US6429194B1 (en) * | 1999-03-01 | 2002-08-06 | Vista Scientific Llc | Mucin containing ophthalmic preparation |
| US6428502B1 (en) * | 1999-06-25 | 2002-08-06 | Alcon Manufacturing, Ltd. | Punctal cannula |
| TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
| AUPQ228199A0 (en) | 1999-08-18 | 1999-09-09 | Sly, Anthony William | Ophthalmic fluid |
| US6286955B1 (en) * | 1999-12-15 | 2001-09-11 | Tetsuya Sakai | Biocompatible lens, and method of producing the same |
| US6344047B1 (en) * | 2000-02-02 | 2002-02-05 | Eagle Vision | Instrument for inserting a punctum plug and method for manufacturing the instrument |
| US6533415B2 (en) * | 2000-03-21 | 2003-03-18 | Menicon Co., Ltd. | Ocular lens material having hydrophilic surface and process for preparing the same |
| GB0012597D0 (en) * | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
| US20020116750A1 (en) * | 2000-08-01 | 2002-08-29 | Korb Donald R. | Visual discomfort relief |
| US6506412B2 (en) * | 2000-11-29 | 2003-01-14 | Sciencebased Health | Treatment of dry eye syndrome |
| US6667047B2 (en) * | 2001-07-27 | 2003-12-23 | International Flute Technologies Ltd | Ultra-stable composition comprising moringa oil and its derivatives and uses thereof |
| US20040076691A1 (en) | 2002-01-16 | 2004-04-22 | David Haines | Anti-inflammatory formulations |
| US20040048926A1 (en) * | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
| DE60318456T2 (de) * | 2002-06-17 | 2008-12-24 | Resolvyx Pharmaceuticals, Bedford | ANALOGA VON OMEGA-3-PUFAs ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN |
| WO2004006801A2 (en) | 2002-07-17 | 2004-01-22 | Biosyntrx, Inc. | Treatment for dry eye syndrome |
| US20060251685A1 (en) * | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050202097A1 (en) * | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
-
2005
- 2005-06-30 JP JP2007520365A patent/JP2008505177A/ja active Pending
- 2005-06-30 WO PCT/US2005/023113 patent/WO2006007510A1/en not_active Ceased
- 2005-06-30 NZ NZ552481A patent/NZ552481A/en unknown
- 2005-06-30 CA CA002572344A patent/CA2572344A1/en not_active Abandoned
- 2005-06-30 MX MX2007000208A patent/MX2007000208A/es not_active Application Discontinuation
- 2005-06-30 US US11/171,815 patent/US20060009522A1/en not_active Abandoned
- 2005-06-30 EP EP05767809.6A patent/EP1781278B2/en not_active Expired - Lifetime
- 2005-06-30 AU AU2005262392A patent/AU2005262392A1/en not_active Abandoned
- 2005-06-30 KR KR1020077002456A patent/KR20070040381A/ko not_active Withdrawn
- 2005-06-30 BR BRPI0512864A patent/BRPI0512864B8/pt not_active IP Right Cessation
- 2005-06-30 RU RU2007103835/15A patent/RU2007103835A/ru not_active Application Discontinuation
- 2005-06-30 CN CNA2005800287299A patent/CN101043884A/zh active Pending
-
2006
- 2006-12-26 IL IL180342A patent/IL180342A0/en unknown
-
2007
- 2007-01-30 NO NO20070561A patent/NO20070561L/no not_active Application Discontinuation
- 2007-01-31 ZA ZA200700918A patent/ZA200700918B/xx unknown
- 2007-10-17 US US11/873,478 patent/US20080153909A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63297323A (ja) * | 1987-05-07 | 1988-12-05 | ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツ プリカーシヨン・シヤンテイフイツク・（エス．セー．エール．アー．エス） | 眼科薬 |
| JPH06122627A (ja) * | 1992-10-13 | 1994-05-06 | Sagami Chem Res Center | 抗アレルギー点眼液 |
| JP2003512312A (ja) * | 1999-10-20 | 2003-04-02 | ヴェジファクト・アクチェンゲゼルシャフト | マイクロエマルジョン予備濃縮物、マイクロエマルジョンおよび組成物の使用 |
| WO2003018049A2 (en) * | 2001-08-23 | 2003-03-06 | Westgate Biological Limited | Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| WO2004004599A2 (en) * | 2002-07-08 | 2004-01-15 | Advanced Vision Research | Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| JP2006526579A (ja) * | 2003-03-18 | 2006-11-24 | アドバンスト メディカル オプティクス， インコーポレーテッド | 自己乳化組成物、その使用および製造方法 |
| JP2005008570A (ja) * | 2003-06-19 | 2005-01-13 | Santen Pharmaceut Co Ltd | 角膜疾患治療剤 |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11324757B2 (en) | 2010-03-17 | 2022-05-10 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US11160865B2 (en) | 2010-10-20 | 2021-11-02 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| JPWO2012067224A1 (ja) * | 2010-11-19 | 2014-05-19 | 日本水産株式会社 | 角膜上皮障害及び／又は結膜上皮障害の治療又は予防剤 |
| US12364679B2 (en) | 2011-06-30 | 2025-07-22 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
| JP2014518261A (ja) * | 2011-06-30 | 2014-07-28 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド | 眼の炎症状態を治療するためのエステル |
| JP2015526515A (ja) * | 2012-08-31 | 2015-09-10 | ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ | オメガ３脂肪酸を有する眼用組成物 |
| US10369117B2 (en) | 2012-09-12 | 2019-08-06 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US10449164B2 (en) | 2012-09-12 | 2019-10-22 | Novaliq Gmbh | Methods of treating ocular disorders using semifluorinated alkanes |
| KR20180101640A (ko) * | 2012-09-12 | 2018-09-12 | 노바리크 게엠베하 | 부분불소화 알칸 조성물 |
| KR20150054997A (ko) * | 2012-09-12 | 2015-05-20 | 노바리크 게엠베하 | 부분불소화 알칸 조성물 |
| KR102115111B1 (ko) | 2012-09-12 | 2020-05-26 | 노바리크 게엠베하 | 부분불소화 알칸 조성물 |
| US12005033B2 (en) | 2012-09-12 | 2024-06-11 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US11583513B2 (en) | 2012-09-12 | 2023-02-21 | Novaliq Gmbh | Semifluorinated alkane compositions |
| KR102171897B1 (ko) | 2012-09-12 | 2020-11-02 | 노바리크 게엠베하 | 부분불소화 알칸 조성물 |
| JP2015531344A (ja) * | 2012-09-12 | 2015-11-02 | ノバリック ゲーエムベーハー | 半フッ化アルカンの混合物を含む組成物 |
| JP2016512245A (ja) * | 2013-03-12 | 2016-04-25 | フィジシャンズ レコメンデッド ニュートリシューティカルズ エルエルシーＰｈｙｓｉｃｉａｎｓ Ｒｅｃｏｍｍｅｎｄｅｄ Ｎｕｔｒｉｃｅｕｔｉｃａｌｓ，Ｌｌｃ | マイボーム腺を標的とする栄養補給剤 |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| US11357738B2 (en) | 2015-09-30 | 2022-06-14 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US11400132B2 (en) | 2016-09-23 | 2022-08-02 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US12496326B2 (en) | 2016-12-23 | 2025-12-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| JP2021529167A (ja) * | 2018-06-19 | 2021-10-28 | エーパックス ノルウェー アクスイェ セルスカプ | ドライアイ疾患及び瞼板腺炎の治療のための組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007103835A (ru) | 2008-08-10 |
| BRPI0512864B1 (pt) | 2021-04-27 |
| ZA200700918B (en) | 2008-10-29 |
| EP1781278A4 (en) | 2009-09-02 |
| NZ552481A (en) | 2008-12-24 |
| BRPI0512864B8 (pt) | 2021-05-25 |
| NO20070561L (no) | 2007-03-30 |
| CA2572344A1 (en) | 2006-01-19 |
| US20080153909A1 (en) | 2008-06-26 |
| MX2007000208A (es) | 2007-08-07 |
| AU2005262392A1 (en) | 2006-01-19 |
| EP1781278A1 (en) | 2007-05-09 |
| CN101043884A (zh) | 2007-09-26 |
| BRPI0512864A (pt) | 2008-04-08 |
| IL180342A0 (en) | 2007-07-04 |
| EP1781278B2 (en) | 2019-10-16 |
| US20060009522A1 (en) | 2006-01-12 |
| EP1781278B1 (en) | 2016-08-10 |
| WO2006007510A1 (en) | 2006-01-19 |
| KR20070040381A (ko) | 2007-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1781278B2 (en) | Compositions and methods for treating eye disorders and conditions | |
| US20070265341A1 (en) | Compositions and methods for treating eye disorders and conditions | |
| KR101677308B1 (ko) | 오메가-3 및 오메가-6 다가 불포화 지방산계 안과용 조성물 | |
| CN103533962B (zh) | 一种眼用组合物 | |
| US4866049A (en) | Ophthalmic compositionn and method of using same | |
| WO1994004155A1 (en) | Dehydroepiandrosterone therapy for the treatment of eye disorders | |
| JP2022506684A (ja) | 人工涙液 | |
| EP3280395B1 (en) | Ophthalmic compositions based on polyunsaturated fatty acids and triacylglycerols | |
| US20010027188A1 (en) | Composition for prophylaxis and/or treatment of dry eye syndrome comprising vitamin D | |
| WO2023055321A1 (en) | Anti-inflammatory microemulsion eye formulations derived from nigella sativa oil | |
| HK1166714B (en) | Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids | |
| WO2025163023A1 (en) | Ophthalmic formulations | |
| Ellingson | Biopharmaceutic considerations in the development of a topical ocular prodrug of ibuprofen | |
| TR2021015389A2 (tr) | Çörek otu yaği kaynakli anti̇i̇nflamatuar etki̇li̇ mi̇kroemülsi̇yon göz formülasyonlari |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110809 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111215 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120531 |